Company / Operating Cash Flow per Share
Zenas BioPharma, Inc. Operating Cash Flow per Share History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$4.12
FY2025
5-year range
-$19.94 / -$4.12
FY2023-FY2025
Trend
+78.7%
vs FY2024
Sector context
#191 of 212
Health Care
What the data says
Among 212 Health Care companies, Zenas BioPharma, Inc. is in the bottom 10% for operating cash flow per share. Improved from $-19.94 to $-4.12 over the past 2 years.
Based on SEC 10-K filings.
-4.12 in FY2025.
Improved from $-19.94 to $-4.12 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 10% in Health CareTop 90% of 212This company -$4.12 Sector average -$14.72
▼
+72.0% above sector average
Key checks
Key Insights
- In FY2025, operating cash flow per share increased 78.7% year-over-year.
- Ranks #191 out of 212 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.51 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$4.12 | +78.7% |
| FY2024 | -$19.36 | +2.9% |
| FY2023 | -$19.94 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026